Girentuximab (cG250) is a chimeric monoclonal antibody that targets carbonic anhydrase IX (CAIX), which is a cell surface antigen expressed in various cancers, such as clear cell renal cell carcinoma (ccRCC), urothelial carcinoma, and TNBC. Here, CA9 is linked to urothelial carcinoma.